Avanir Pharmaceuticals

Lidak Pharmaceuticals

Quidel Corporation

Mohammed H Khalil

David H Katz

Laura E Pope

John F Marcelletti

Lee R Katz

Robert B Sargeant

Robert W Eisinger

The present invention is related to antiviral compositions comprising long-chain aliphatic compounds in combination with a nucleoside analog or phosphonoformic acid, in a pharmaceutically acceptable carrier. Methods for treating viral infections using such compositions are also disclosed.

Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs

A method is disclosed for treating a benign or malignant hyperproliferative skin lesion, comprising topically administering a C18 to C20 aliphatic alcohol to the skin lesion in a pharmaceutically acceptable carrier.

Treatment of hyperproliferative skin disorders with C18 to C20 aliphatic alcohols

Therapeutic compositions including a nonionic surfactant combined with long chain fatty acids, alkanes, amides or mono-unsaturated alcohols, particularly stearyl alcohol, erucyl alcohol, brassidyl alcohol, arachidyl alcohol, n-docosane, n-docosanoic acid, erucamide and stearic acid, or mixtures thereof, as active ingredients are disclosed. Methods of preventing or treating viral infections, treating skin or membrane inflammation or inhibiting cell proliferation using such compositions are disclosed.

Long-chain alcohols, alkanes, fatty acids and amides in the treatment of

A method for treating a benign or malignant hyperproliferative skin lesion, comprising topically administering a C18 to C26 aliphatic alcohol to the skin lesion in a pharmaceutically acceptable carrier.

Treatment of hyperproliferative skin disorders with C18 to C26 alphatic

A stable, efficacious therapeutic cream wherein a principal therapeutic compounds are one or more C-20 to C-28 long chain aliphatic alcohols, of which n-docosanol is exemplary, comprising sucrose cocoate, sucrose stearates or sucrose distearate, or mixtures thereof, is disclosed.

Sucrose ester-C20 to C28 alcohol formulations

A method and apparatus for conducting specific binding pair assays, such as immunoassays, is described. A porous membrane capable of non-bibulous lateral flow is used as assay substrate; a member of the binding pair is affixed in an indicator zone defined in the substrate. The sample is applied at a position distant from the indicator zone and permitted to flow laterally through the zone; any analyte in the sample is complexed by the affixed specific binding member, and detected. A novel method of detection employs entrapment of observable particle in the complex. Blood is a particularly preferred sample as the red blood cells can be used as the observable particles for detection of the complex.

Growing community of inventors

San Diego, CA, United States of America

Mohammed H Khalil